Wales' drug authority recommends Sprycel

28 January 2008

The All Wales Medicines Strategy Group has recommended that Sprycel (dasatinib), which is manufactured by US drug major Bristol-Myers Squibb, should be used within the National Health Service in Wales for the treatment of adults with chronic or accelerated phase chronic myeloid leukemia, where there is resistance or intolerance to prior therapy including Novartis' Glivec/Gleevec (imatinib mesylate).

The disease is rare, but accounts for around 15% of all leukemias, with about 2,600 people in the UK currently affected by CML. The condition progresses through three stages: chronic, accelerated and blast. Sprycel was not recommended by the AWMSG in blast phase patients. However, B-MS notes that, because most CML patients are diagnosed in the chronic phase, this recommendation will encompass the majority of eligible patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight